Want to take quizzes and track your credits?
What was the association of the COVID-19 pandemic with cancer screening rates across the US?
This cohort study found that with sharp declines and subsequent recoveries of breast, colorectal, and prostate cancer monthly screening rates in 2020, there remained an estimated screening deficit of 9.4 million associated with the COVID-19 pandemic for the US population. Screening declines differed by geographic region and socioeconomic status index, and use of telehealth was associated with higher screening rates.
Public health efforts are needed to make up the large cancer screening deficit associated with the COVID-19 pandemic.
The COVID-19 pandemic led to sharp declines in cancer screening. However, the total deficit in screening in the US associated with the pandemic and the differential impact on individuals in different geographic regions and by socioeconomic status (SES) index have yet to be fully characterized.
To quantify the screening rates for breast, colorectal, and prostate cancers associated with the COVID-19 pandemic in different geographic regions and for individuals in different SES index quartiles and estimate the overall cancer screening deficit in 2020 across the US population.
Design, Setting, and Participants
This retrospective cohort study uses the HealthCore Integrated Research Database, which comprises single-payer administrative claims data and enrollment information covering approximately 60 million people in Medicare Advantage and commercial health plans from across geographically diverse regions of the US. Participants were individuals in the database in January through July of 2018, 2019, and 2020 without diagnosis of the cancer of interest prior to the analytic index month.
Analytic index month and year.
Main Outcomes and Measures
Receipt of breast, colorectal, or prostate cancer screening.
Screening for all 3 cancers declined sharply in March through May of 2020 compared with 2019, with the sharpest decline in April (breast, −90.8%; colorectal, −79.3%; prostate, −63.4%) and near complete recovery of monthly screening rates by July for breast and prostate cancers. The absolute deficit across the US population in screening associated with the COVID-19 pandemic was estimated to be 3.9 million (breast), 3.8 million (colorectal), and 1.6 million (prostate). Geographic differences were observed: the Northeast experienced the sharpest declines in screening, while the West had a slower recovery compared with the Midwest and South. For example, percentage change in breast cancer screening rate (2020 vs 2019) for the month of April ranged from −87.3% (95% CI, −87.9% to −86.7%) in the West to −94.5% (95% CI, −94.9% to −94.1%) in the Northeast (decline). For the month of July, it ranged from −0.3% (95% CI, −2.1% to 1.5%) in the Midwest to −10.6% (−12.6% to −8.4%) in the West (recovery). By SES, the largest screening decline was observed in individuals in the highest SES index quartile, leading to a narrowing in the disparity in cancer screening by SES in 2020. For example, prostate cancer screening rates per 100 000 enrollees for individuals in the lowest and highest SES index quartiles, respectively, were 3525 (95% CI, 3444 to 3607) and 4329 (95% CI, 4271 to 4386) in April 2019 compared with 1535 (95% CI, 1480 to 1589) and 1338 (95% CI, 1306 to 1370) in April 2020. Multivariable analysis showed that telehealth use was associated with higher cancer screening.
Conclusions and Relevance
Public health efforts are needed to address the large cancer screening deficit associated with the COVID-19 pandemic, including increased use of screening modalities that do not require a procedure.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: March 9, 2021.
Published Online: April 29, 2021. doi:10.1001/jamaoncol.2021.0884
Corresponding Author: Ronald Chen, MD, MPH, Department of Radiation Oncology, University of Kansas, Kansas City, KS 66160 (firstname.lastname@example.org).
Author Contributions: Drs Chen and Katz had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Chen, Haynes, Du, Katz.
Drafting of the manuscript: Chen, Katz.
Critical revision of the manuscript for important intellectual content: Haynes, Du, Barron, Katz.
Statistical analysis: Katz.
Administrative, technical, or material support: Chen, Haynes.
Supervision: Chen, Barron.
Conflict of Interest Disclosures: Dr Chen reported receiving personal fees from AbbVie, Myovant, Bayer, Blue Earth Diagnostics, and Accuray outside the submitted work. Dr Haynes reported being employed by Anthem during the conduct of the study; receiving grants from Patient-Centered Outcomes Research Institute and contracts from the US Food and Drug Administration outside the submitted work. Dr Du reported receiving personal fees (salary) from HealthCore during the conduct of the study. Dr Barron reported being an Anthem employee and stock shareholder. Dr Katz reported receiving personal fees from Kite Pharma and Atara Biotherapeutics outside the submitted work.
You currently have no searches saved.